<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-11-20T18:38:35.081Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-11-20T18:38:35.081Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-11-20T18:38:35.081Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-11-20T18:38:35.081Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-11-20T18:38:35.081Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/NVO:1795197695000</loc>
    <lastmod>2026-11-20T18:01:35.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>FDA Approves Novo Nordisk&#39;s Sogroya® for Turner Syndrome in Children</image:title>
      <image:caption>The FDA approved Novo Nordisk’s once-weekly growth hormone Sogroya (somapacitan-beco) for children aged 2.5 years and older with growth failure associated with Turner Syndrome. The decision was supported by efficacy and safety results from the pivotal REAL8 trial. Sogroya is now indicated for growth hormone deficiency and four other growth-related conditions, including Idiopathic Short Stature, Noonan Syndrome, and short stature in children born Small for Gestational Age.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/ELCO:1795195966000</loc>
    <lastmod>2026-11-20T17:32:46.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ELCO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>High Court Sanctions Eleco plc Takeover by Avocet Bidco</image:title>
      <image:caption>The High Court sanctioned Avocet Bidco Limited’s recommended all-cash acquisition of Eleco plc; Avocet is managed by Accel-KKR. Eleco shares are scheduled to trade for the final time on 27 November 2026, with AIM trading suspended on 30 November and admission cancelled on 1 December; shareholder payments are expected by 14 December. The transaction also triggered the exercise of 2.44 million employee and executive share options, including options held by CEO Jonathan Hunter and CFO Neil Pritchard.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/SPI:1795195955000</loc>
    <lastmod>2026-11-20T17:32:35.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/SPI/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>UK Financial Regulator Clears Tulip UK Bidco&#39;s Takeover Offer for Spire Healthcare</image:title>
      <image:caption>The UK financial regulator has cleared Tulip UK Bidco’s takeover offer for Spire Healthcare Group plc, advancing the acquisition toward completion. The approval follows recent shareholder support; the article reports no financial terms or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/FRP:1795195894000</loc>
    <lastmod>2026-11-20T17:31:34.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/FRP/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>FRP Advisory Group plc Announces H1 2027 Trading Update</image:title>
      <image:caption>FRP Advisory Group reported first-half FY2027 revenue of £98 million, up from £87.1 million a year earlier, and adjusted EBITDA of £25 million versus £23 million. It said all service pillars performed strongly, particularly corporate finance, with clients seeking to complete deals ahead of the 2026 Autumn Budget. Unaudited net cash stood at £15.5 million as of 31 October 2026, and the company said it remains on track to meet consensus full-year expectations of £184 million in revenue and £48 million in adjusted EBITDA.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/INPST:1795194105000</loc>
    <lastmod>2026-11-20T17:01:45.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/INPST/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Consortium of Advent, FedEx, A&amp;R, and PPF Completes Acquisition of InPost</image:title>
      <image:caption>A consortium of Advent International, FedEx, A&amp;R Investments, and PPF Group completed its acquisition of InPost, making the company wholly owned by the consortium and delisted from Euronext Amsterdam. InPost will continue operating independently from Poland, with its headquarters and management team unchanged. CEO and founder Rafał Brzoska will remain in charge, while the new owners plan to provide capital and sector expertise to support European expansion.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/IWS:1795192330000</loc>
    <lastmod>2026-11-20T16:32:10.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/IWS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Integrated Wind Solutions Reports Q3 2026 Results with Record EPS and New Vessel Orders</image:title>
      <image:caption>Integrated Wind Solutions ASA reported record-high earnings per share for the third quarter of 2026. The company also ordered four newbuildings to expand its fleet. The results and orders were disclosed through official regulatory channels on Euronext.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/XTP:1795192323000</loc>
    <lastmod>2026-11-20T16:32:03.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/XTP/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>sino AG Reports Preliminary Financial Results for Fiscal Year 2025/2026</image:title>
      <image:caption>sino AG reported preliminary consolidated net profit of approximately €40.4 million for fiscal 2025/2026, up from €1.0 million a year earlier. Its individual net profit was €40.5 million, largely reflecting sino Beteiligungen GmbH’s partial sale of shares in Trade Republic Bank GmbH. Management plans to propose a dividend of at least €14.80 per share. Orders processed rose 42.74% year over year, despite fewer arbitrage opportunities following the decline of payment for order flow.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/WLN:1795192304000</loc>
    <lastmod>2026-11-20T16:31:44.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/WLN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Worldline Faces Allegations of Cash Flow Manipulation</image:title>
      <image:caption>Reports citing internal messages and a PwC audit allege that Worldline artificially inflated free cash flow between 2021 and 2023 by delaying supplier payments and seeking early payments from clients before reporting periods. Worldline denied the allegations, saying its accounts are reviewed by audit committees, approved by the board, and certified by auditors in accordance with regulations. The company said the claims concern past periods and harm its reputation; the article gives no financial figures or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/DMP:1795192293000</loc>
    <lastmod>2026-11-20T16:31:33.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/DMP/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>BaFin Identifies Errors in Dermapharm&#39;s 2025 Consolidated Financial Statements</image:title>
      <image:caption>BaFin concluded that Dermapharm Holding SE’s 2025 consolidated financial statements were erroneous, citing two accounting violations. The company failed to record at least €1.9 million in impairment on a €63.2 million receivable, overstating other long-term assets under IFRS 9. It also failed to disclose that business volume with its parent company rose from €7.0 million to €70.8 million, primarily because of a €70.0 million loan, contrary to IAS 24.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MLHK:1795192286000</loc>
    <lastmod>2026-11-20T16:31:26.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MLHK/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Heckler &amp; Koch Secures Major Contract from French Procurement Agency</image:title>
      <image:caption>Heckler &amp; Koch won a French procurement agency contract to deliver more than 70,000 assault rifles and accessories over ten years. France has received approximately 100,000 rifles from the German manufacturer since its first major order in 2016. The company did not disclose the new contract’s financial value.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BAYN:1795188699000</loc>
    <lastmod>2026-11-20T15:31:39.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BAYN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Bayer&#39;s SUNHARBO® (asundexian) Now Available in the United States</image:title>
      <image:caption>Bayer has launched SUNHARBO® (asundexian) 50 mg tablets in the United States, where it is immediately available for order by healthcare providers and pharmacies. The drug is the first Factor XIa inhibitor approved in the U.S. and is indicated alongside antiplatelet therapy to reduce stroke risk in adults who recently experienced a non-cardioembolic ischemic stroke. The article reports no financial figures or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MOG.A:1795185171000</loc>
    <lastmod>2026-11-20T14:32:51.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MOG.A/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Moog Reports Fiscal Q4 Financial Results and Fiscal 2027 Outlook</image:title>
      <image:caption>Moog reported fiscal fourth-quarter adjusted earnings per share of $3.37, above the FactSet consensus estimate of $2.69, and net sales of $1.25 billion, exceeding expectations of $1.12 billion. For fiscal 2027, the company projects net sales of $4.95 billion and adjusted EPS of $13.30, above analyst estimates of $4.73 billion and $12.14, respectively.</image:caption>
    </image:image>
  </url>
</urlset>